STING agonist at antigen release, addressing sub-threshold loading
STING agonist (sting pathway agonism) acts at the antigen release step of the cancer-immunity cycle. The failure mode is sub-threshold loading: loading current never raises charge to threshold. Capacitor never fires; Activation barrier permanently inert.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), STING agonist acts via sting pathway agonism. The failure mode is sub-threshold loading: loading current never raises charge to threshold. Capacitor never fires; Activation barrier permanently inert. The intervention's regime-type class lines up with the position's regime, and failure_sub_threshold_loading belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_sub_threshold_loading
Evidence at generation
"sting agonist" AND "cancer immunotherapy"
- PMID 36705879
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
- PMID 39744236
A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy.
- PMID 38559305
Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.
- PMID 34070756
STING Agonists as Cancer Therapeutics.
- PMID 39548120
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.
Targets: —
Not found in ChEMBL: STING agonist
sting agonist cancer immunotherapy
- NCT05846646
Oligometastatic Disease
Primary: Anti-tumor Effects
- NCT05846659
Oligoprogressive
Primary: Anti-tumor Effects
Status timeline
- Draft2026-05-28T23:27:38Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system
- Published2026-05-29T06:35:42Z
Published as part of the first 5-hypothesis daily batch. Engine v0.1.1: verb_target-aware combinatorial walker, sub-regime failure pool, lowercase evidence queries. Operator review pass: kept as-is.
by raimo